Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA

OBJECTIVES: Evaluating the cost-effectiveness of pembrolizumab plus standard chemotherapy in the first-line setting for patients with metastatic non-small cell lung cancer (NSCLC) from the US payer perspective. DESIGN: A Markov model was constructed to analyse the cost-effectiveness of pembrolizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Xiaohui, Wan, Xiaomin, Peng, Liubao, Peng, Ye, Ma, Fang, Liu, Qiao, Tan, Chongqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924863/
https://www.ncbi.nlm.nih.gov/pubmed/31831534
http://dx.doi.org/10.1136/bmjopen-2019-031019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924863/
https://www.ncbi.nlm.nih.gov/pubmed/31831534
http://dx.doi.org/10.1136/bmjopen-2019-031019

Ejemplares similares